The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALPHABET INC | CAP STK CL C | 02079K107 | 10,382 | 15,000 | SH | SOLE | 15,000 | 0 | 0 | ||
| AMGEN INC | COM | 031162100 | 6,086 | 40,000 | SH | SOLE | 40,000 | 0 | 0 | ||
| HCA HOLDINGS INC | COM | 40412C101 | 7,701 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| NEOPHOTONICS CORP | COM | 64051T100 | 2,859 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
| NEXPOINT RESIDENTIAL TR INC | COM | 65341D102 | 11,100 | 609,905 | SH | SOLE | 609,905 | 0 | 0 | ||
| THERAVANCE BIOPHARMA INC | COM | G8807B106 | 7,374 | 325,000 | SH | SOLE | 325,000 | 0 | 0 | ||